BNP Paribas Financial Markets Takes $2.97 Million Position in Certara, Inc. (NASDAQ:CERT)

BNP Paribas Financial Markets purchased a new stake in shares of Certara, Inc. (NASDAQ:CERT - Free Report) during the 4th quarter, according to the company in its most recent filing with the SEC. The fund purchased 279,061 shares of the company's stock, valued at approximately $2,972,000. BNP Paribas Financial Markets owned about 0.17% of Certara as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Vanguard Group Inc. raised its stake in Certara by 0.3% in the 4th quarter. Vanguard Group Inc. now owns 12,437,089 shares of the company's stock valued at $132,455,000 after purchasing an additional 38,068 shares during the last quarter. ArrowMark Colorado Holdings LLC raised its stake in shares of Certara by 164.2% in the 4th quarter. ArrowMark Colorado Holdings LLC now owns 6,213,278 shares of the company's stock valued at $66,171,000 after acquiring an additional 3,861,674 shares during the period. Teacher Retirement System of Texas boosted its holdings in Certara by 13.9% during the 4th quarter. Teacher Retirement System of Texas now owns 4,557,951 shares of the company's stock valued at $48,542,000 after acquiring an additional 557,348 shares during the period. Massachusetts Financial Services Co. MA increased its position in shares of Certara by 4.7% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 4,083,940 shares of the company's stock worth $43,494,000 after acquiring an additional 182,042 shares during the period. Finally, Brown Brothers Harriman & Co. raised its stake in shares of Certara by 63.8% in the fourth quarter. Brown Brothers Harriman & Co. now owns 3,818,613 shares of the company's stock valued at $40,668,000 after acquiring an additional 1,487,998 shares in the last quarter. Institutional investors and hedge funds own 73.96% of the company's stock.

Analysts Set New Price Targets

A number of brokerages recently issued reports on CERT. Stephens reaffirmed an "overweight" rating and issued a $17.00 price target on shares of Certara in a report on Thursday, February 27th. TD Cowen began coverage on Certara in a research report on Thursday, February 27th. They set a "buy" rating and a $16.00 price target on the stock. Barclays upgraded shares of Certara from an "equal weight" rating to an "overweight" rating and raised their target price for the stock from $11.00 to $14.00 in a research report on Thursday, May 8th. William Blair reaffirmed a "market perform" rating on shares of Certara in a report on Thursday, February 27th. Finally, KeyCorp increased their price target on Certara from $15.00 to $18.00 and gave the stock an "overweight" rating in a report on Wednesday, April 16th. Three investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $15.67.

Certara Price Performance

Shares of NASDAQ CERT traded down $0.48 during trading on Wednesday, hitting $11.21. 235,750 shares of the company were exchanged, compared to its average volume of 1,310,774. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.86 and a quick ratio of 2.86. Certara, Inc. has a 1 year low of $8.64 and a 1 year high of $17.76. The company has a market cap of $1.82 billion, a price-to-earnings ratio of -56.13, a PEG ratio of 9.29 and a beta of 1.57. The firm's fifty day moving average price is $11.76 and its 200 day moving average price is $11.75.

Certara (NASDAQ:CERT - Get Free Report) last announced its quarterly earnings data on Monday, May 5th. The company reported $0.14 EPS for the quarter, beating the consensus estimate of $0.10 by $0.04. Certara had a negative net margin of 8.34% and a positive return on equity of 3.43%. The firm had revenue of $106.00 million during the quarter, compared to analysts' expectations of $104.44 million. During the same quarter last year, the business earned $0.10 earnings per share. The business's revenue for the quarter was up 9.7% compared to the same quarter last year. On average, sell-side analysts expect that Certara, Inc. will post 0.28 earnings per share for the current fiscal year.

Certara Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.